EU Regulators Fine Johnson & Johnson, Novartis AG 16 Million Euros For Generic Drug Deal

Published: Dec 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

European Union antitrust regulators fined drugmakers Johnson & Johnson and Novartis a total of 16 million euros ($21.95 million) on Tuesday for blocking the sale of a generic painkiller in the Dutch market. The European Commission said in a statement that the deal between the two companies meant patients did not have access to the cheaper generic version of fentanyl for 17 months starting from July 2005. Johnson & Johnson and its Dutch unit, Janssen-Cilag, were fined 10.8 million euros while Novartis and its Dutch subsidiary, Sandoz, were fined 5.5 million euros.

Help employers find you! Check out all the jobs and post your resume.

Back to news